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The antimalarial screening landscape—looking beyond
the asexual blood stage
Sabrina Yahiya1, Ainoa Rueda-Zubiaurre2, Michael J Delves3,
Matthew J Fuchter2 and Jake Baum1
In recent years, the research agenda to tackle global morbidity
and mortality from malaria disease has shifted towards
innovation, in the hope that efforts at the frontiers of scientific
research may re-invigorate gains made towards eradication.
Discovery of new antimalarial drugs with novel chemotypes or
modes of action lie at the heart of these efforts. There is a
particular interest in drug candidates that target stages of the
malaria parasite lifecycle beyond the symptomatic asexual
blood stages. This is especially important given the spectre of
emerging drug resistance to all current frontline antimalarials.
One approach gaining increased interest is the potential of
designing novel drugs that target parasite passage from
infected individual to feeding mosquito and back again. Action
of such therapeutics is geared much more at the population
level rather than just concerned with the infected individual.
The search for novel drugs active against these stages has
been helped by improvements to in vitro culture of
transmission and pre-erythrocytic parasite lifecycle stages,
robotic automation and high content imaging, methodologies
that permit the high-throughput screening (HTS) of compound
libraries for drug discovery. Here, we review recent advances
in the antimalarial screening landscape, focussed on
transmission blocking as a key aim for drug-treatment
campaigns of the future.
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Introduction
Incredible progress has been made in reducing the global
malaria burden since the declaration of theUN Millennium
Development Goals in 2000. However, in recent years,
progress has stalled, with incidence and death rates from
malaria no longer declining [1]., Commitment to these
goals triggered a spike in global funding and interest,
resulting in an increased implementation of artemisinin
combinationtherapies (ACTs), insecticide treated bednets
(ITNs) and indoor residual spraying (IRS) which was
pivotal in addressing the global burden of malaria disease
[2]. Parasite resistance to artemisinin, its derivatives and
partner drugs [3] and mosquito resistance to insecticides
are, therefore, key challenges to get reduction of malarial
incidence back on track. It is increasingly acknowledged
that a focus on innovation, and not just implementation of
the current antimalarial armamentarium, is required to
overcome these challenges [4,5]. New drugs, with novel
chemical structures and new modes of action (MoA), will
likely be a key component of such innovation [5].
Many groups active in antimalarial drug discovery, coordi-
nate their work within a framework of molecule type [target
candidate profiles (TCP)],meaningthe lifecyclestagewhich
is compromised by the drug, and medicine class (target
product profiles (TPP)], the final drug formulation defined
as a combination of TCPs, developed by the not-for-profit
Medicines for Malaria Venture, MMV [6] (Table 1).
Sought after characteristics include activity against asymp-
tomatic stages (TCP3-5), endectocides targeting the mos-
quito (TCP-6) and symptomatic asexual blood stages (ABS),
classified as TCP-1 (Table 1). Profiles meet different needs
such as medicines for clinical case management, chemopro-
tection for travellers, and those aimed at breaking population
transmission. Protection of the uninfected population is
crucial for eventual local elimination of transmission, and
can be achieved by either targeting the mosquito (via vector
control, bite-prevention or endectocides) or via compounds
with transmission blocking activity [6]. One long-sought
goal for optimal treatment formulation is the administration
of a Single Encounter Radical Cure and Prophylaxis (SER-
CaP), removing blood parasitemia and the longer-lived
parasite reservoir from patients for both radical cure and
elimination of future transmission, all in one go [5].
Drug Discovery by screening
In recent years, great emphasis has been placed on high-
throughput screening (HTS) of large compound libraries,
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to find novel therapeutics having a new MoA, combined
with improvement of existing compounds through medic-
inal chemistry and structure activity relationship (SAR)
studies. High-throughput screens (HTS) are generally
categorised into two types: target-specific assays (usually
biochemical) or whole-cell (phenotypic) tailored to meet
the different TCP/TPP criteria [7]. Given the breadth in
the literature of both, here we centre our discussion on
phenotypic (specifically cellular) screens, with a particular
focus on P. falciparum, the most virulent parasite causing
malaria in humans [8].
Although in vitro culture of P. falciparum is routine,
automation, liquid handling and high-throughput imag-
ing have played key roles in recent advancements in HTS
capacity [7]. This has been markedly helped by efforts
from the chemical vendor industry and pharma to provide
access of compound libraries to smaller institutions and
academic research groups, permitting testing on a massive
scale, often with millions of compounds. Combined with
assay miniaturisation, this has led to development of
robust, inexpensive, and reproducible screens, typically
utilising 384- or 1536-well plate-based formats [7,9]. To
date, the vast majority of screening campaigns have
centred on ABS. Recently, however, this has expanded
to transmission and pre-erythrocytic stages, including
development of screening platforms for sporozoites
[10], sexual stage gametocytes [11], gametes [12], ooki-
netes [13] and liver stages [14]. In either context, parasite
cultures are incubated with compounds of interest and
parasite survival is determined as an assay readout. Struc-
tures and activity of antimalarial compounds derived from
such phenotypic screens are then deposited in the
chEMBL Neglected Tropical Disease archive [15].
Asexual Blood Stage (ABS) screens
Novel compounds targeting asexual blood stages (under
the umbrella of TCP-1) have long been seen as a priority
in antimalarial research, being the causative agent of
symptoms associated with malaria [6]. The first
P. falciparum ABS screen (indeed the first major HTS)
tested 1.7 million compounds from the Genomics Insti-
tute of the Novartis Research Foundation (GNF) Chem-
ical Library, identifying 6000 hits [16]. Similar screens
followed using 300 000 compounds of the St. Jude Chil-
dren’s Research Hospital (SJCRH) chemical library [17];
250 000 compounds from the Griffiths University library
[18]; and, possibly the largest study, from GlaxoSmithK-
line who screened almost 2 million compounds [19]. This
latter screen yielded an enriched library of >13 500 future
potential antimalarials, called the Tres Cantos antimalar-
ial compound set (TCAMS) that has since seeded several
other screens (for example, Refs. [20–23]). The numerous
asexual blood stage screens performed to date, each using
very different methodologies (Figure 1), have identified
thousands of hits, some of which have progressed to
developmental antimalarials, such as the spirondolone
KAE609 (Cipargamin, Figure 2) [24].
Liver stage screens
Beyond ABS, in recent years, the search for novel anti-
malarials has pushed for drugs targeting other stages of
the parasite lifecycle. Plasmodium hepatic forms have
recently gained significant traction due to improved
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Table 1
Classifications of Medicines for Malaria Venture TCP and TPPs
Target Candidate Profiles
Profile Plasmodium lifecycle stage target Notes
TCP1
Asexual blood stages Active against resistant strains of PlasmodiumSymptomatic treatment
TCP3
Dormant liver-stage hypnozoites Improved safety compared to primaquine and tafenoquineAnti-relapse
TCP4
Hepatic schizonts Effective at equal/lower dose to TCP1 treatmentChemoprotection
TCP5
Gametocytes/Gametes Low dose, less than TCP1 treatmentTransmission blocking
TCP6
Insect vector (endectocides) Low dose, less than TCP1 treatmentTransmission blocking
Target Product Profiles
Profile TCPs Addressed Notes
TPP1 TCP1 Single or multiple treatment medicines for treatment of: Severe malaria (TCP1)
TCP3 Uncomplicated malaria and preventative treatment (TCP1)
Case Management TCP5 Relapsing malaria (TCP3)
TCP6 Asymptomatic stages for population protection (TCP5 & 6)
TPP2 TCP1
In the case of epidemics or for migratory populationsChemoprotection TCP4
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Figure 1
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The Plasmodium parasite lifecycle highlighting notable cell-based screens and Target Candidate Profiles (TCP) for developmental drugs.
The Plasmodium lifecycle occurs in stages between a mosquito vector and vertebrate host covering many different sites for drug intervention.
Inoculation of motile sporozoites during the female Anopheles mosquito bloodmeal commences the asymptomatic liver stage. Exclusively to
P. vivax and P. ovale, a proportion of liver-stage parasites form dormant hypnozoites (TCP3). Rupture of hepatic schizonts (TCP4) releases small
merozoite forms that initiate the symptomatic stages (ABS, TCP1) made up of cycles of erythrocyte invasion, replication and release. A proportion
of ABS parasites, rather than divide, commit to sexual differentiation to form the transmissible male and female gametocytes (TCP5), developing
over 8–12 days (for P. falciparum), likely in the bone marrow, through morphologically distinct stages with sexual dimorphism most apparent at the
mature stage V. Upon uptake to the mosquito during a bloodmeal, gametogenesis (formation of mature gametes), is induced rapidly (10–15 min).
This follows environmental cues in the mosquito midgut, including a rise in pH, drop in temperature and the presence of xanthurenic acid, a
mosquito-derived excretory product. Gametogenesis commences with the rounding up of both male and female gametocytes and their egress
from the host erythrocyte. Male gamete formation, or exflagellation, is a remarkably rapid and tightly regulated process. The process includes
three rounds of DNA replication alternating with endomitotic division, followed by the release of eight motile haploid male gametes. Fusion of male
and female gametes ensues, leading to formation of a motile zygote that eventually colonizes the mosquito midgut, reseeding the vector for a new
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culture techniques, opening up possibilities for finding
drugs with causal chemoprophylaxis against liver stages
(TCP4) and those that may target the dormant hypno-
zoite stage (unique to P. vivax and P. ovale species)
classified as TCP3 [25]. Targeting either form hits a
natural bottleneck in the parasite lifecycle, and, therefore,
a powerful way to reduce the probability of drug resis-
tance developing [26]. One challenge remaining, how-
ever, is the need for complete parasite development in
the mosquito, required to obtain infective sporozoites to
seed assays, and the poor rates of in vitro hepatocyte
infectivity. Relatively robust assays are starting to emerge
for in vitro development [14,27], suggesting a turning
point in liver stage screening studies. Liver stage screens
are often focused on smaller libraries of commercially
available compounds with known activity against the
asexual blood stages.
One of the first liver-stage screens (Novartis-GNF Malaria
Box) identified a lead imidazolopiperazine scaffold. This
screen was performed using immunolabelled parasites to
determine the ratio of parasitemia to host nuclei, using a
high-content imaging system [28]. Lead optimisation
yielded a drug candidate, KAF156 (Figure 2) [28], which
is not only active against ABS and liver stages, but also
blocks parasite transmission. KAF156 is currently under-
going clinical trials [29]. Another focused screen tested
1037 existing drugs, also by high-content imaging, to detect
fluorescent murine malaria parasite, P. berghei, liver stages,
identifying decoquinate, a compound with activity against
the parasite mitochondrial bc1 complex [30]. Two addi-
tional screens worth noting used the TCAMS library, to
identify 103 hits with dual inhibitory activity against blood
and liver stages [23] and an ultra-HTS format luciferase-
based assay, that tested both an open access library of small
molecules with confirmed activity against P. falciparum
ABS (the MMV malaria box) and a Diversity-Oriented
Synthesis library from the Broad Institute [31] (Figure 1).
Very recently, a landmark screen of half a million com-
pounds from Charles River [66], consisting of small
molecules with an average weight of 369 Daltons, found
more than 600 hits with sub-micromolar IC50s using a plate-
based P. berghei assay (and validating assays with P. vivax
and P. falciparum) similar to that developed in [31]. Hits
included mitochondrial inhibitors and several others with
potentially novel modes of action.
Although these screens have advanced the pre-erythro-
cytic targeting pipeline, at present, the only existing
liver-stage targeted drugs in use and suited to targeting
the hypnozoite stages are primaquine and tafenoquine
(Figure 2). Both, however, are also associated with intra-
vascular haemolysis in glucose-6-phosphate dehydroge-
nase (G6PD)-deficient patients [32]. The absence of an
accepted P. vivax hypnozoite model is in part to blame for
the limited anti-hypnozoite antimalarial discovery. The
most robust platform for screening was, until recently, a
low throughput in vivo imaging assay using P. cynomolgi
and rhesus monkeys. An in vitro improvement to this
using P. cynomolgi sporozoites and primary monkey hepa-
tocytes [33] has successfully identified a hypnozoitocidal
compound, KAI407 (Figure 2), that besides targeting the
ABS is active against both liver developing parasites and
hypnozoites [34]. Further advances in culture protocols
and use of humanized mouse models add to the tool base
towards the hoped-for radical cure treatment that would
eliminate liver stages [35,36]. Although not yet adapted to
an HTS format, one such assay [35,36] allowed for the
identification of a compound, TM2-115, (Figure 2) a
proposed Plasmodium histone methyltransferase inhibitor
[37] with a unique “wake and kill” phenotype.
Transmission blocking assays
Beyond liver stages, there is a growing awareness of the
potential for targeting parasite transmission, diverting
away from simply treating symptomatic (or pre-symptom-
atic) forms of parasite infection. Targeting transmission
has long been seen as a critical step towards meeting the
demanding goals of an eradication agenda [38]. Although
billions of parasites may circulate an infected individual
during asexual stages, only 0.2–1% are thought to commit
to sexual development and, therefore, are responsible for
transmission, constituting a massive lifecycle bottleneck
[39]. This stage is permissive for transmission to the
mosquito upon uptake of a blood meal, making them a
viable transmission blocking drug target [39].
Drug targeting strategies focussed on transmission centre
on two areas, either breaking transmission by targeting
the mosquito vector itself (using endecticides such as
Ivermectin [40]), classified as TCP6 (recently reviewed
in [41]), or targeting the Plasmodium sexual stages, block-
ing gametocyte or gamete development, classified as
TCP5 [6]. By stopping onward transmission, each is
orientated towards protecting the wider population rather
than the individual [42]. Although several platforms for
discovering transmission blocking drugs have been devel-
oped (Figure 1), advances in screening for compounds
4 Next Generation Therapeutics
(Figure 1 Legend Continued) round of human infection [39]. Notable ABS cellular screens include those against the GNF Library; SJCRH
(identifying hits with 50% inhibitory activity (IC50) of 2 mM); Griffiths University library (identifying hits for physicochemical and chemical diversity
analysis) and TCAMS from GSK. Screens against the asymptomatic liver stages include screens of the Novartis-GNF Malaria Box (potent against
ABS stages); bioactives library of commercially sourced compounds in clinical or pre-clinical development; TCAMS library (hits with dual blood
and liver-stage activity) and the ultra-HTS of the MMV Malaria Box, DOS and most-recently Charles River libraries (hits with submicromolar
exoerythrocytic stage activity). Transmission blocking screens to find drugs that block parasite transmission, compromising gametocyte or gamete
viability, include those against the TCAMS library; LOPAC library using alamarBlue; MMV Malaria Box, GNF library and DOS library (using SaLSSA)
and the Dundee GHCDL (using the DGFA).
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Figure 2
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Notable frontline antimalarials with targets throughout the lifecycle.
Selected antimalarials with activity against different stages of the parasite lifecycle. "Me" denotes methyl groups. KAE609 is a PfATP4 inhibitor
which shows fast parasite clearance and transmission-blocking potential and is currently undergoing phase II clinical trials. Decoquinate is a dual-
stage antimalarial (ABS and liver) with activity against the parasite mitochondrial bc1 complex. Primaquine and tafenoquine are the only liver-stage
targeted compounds with the ability to kill hypnozoites in use despite their side effects. KAI407 is a hypnozoitocidal compound identified using P.
cynomolgi sporozoites and primary monkey hepatocytes that targets the ABS and developing liver stage parasites as well. TM2-115 is a putative
histone methyltransferase inhibitor with activity against both asexual and sexual stages, and the ability to induce dormant liver stages to resume
their maturation. Methylene blue is a classical antimalarial showing transmission-blocking activity regardless of assay read-out and can thus be
used as positive control in screening campaigns. DD01035881 is a male-gamete formation inhibitor identified from the GHCDL screen. KAF156 is
a drug candidate with activity against ABS, liver and sexual stages, which was developed through the optimisation of a hit identified in one of the
first liver stage screens. DDD107498 is a eEF2 inhibitor with activity across all parasite stages. Primaquine, Tafenoquine and DDD1035881 are
used as racemates.
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targeting sexual development have been boosted by
improvements to in vitro culture protocols for
P. falciparum gametocytes [43,44,45]. Being non-repli-
cative developmental stages, however, gametocytes are
not amenable to traditional DNA replication or cell
proliferation markers, which has meant other measures
of viability, including mitochondrial activity or fluores-
cent protein expression are required. Control compounds
often used in such assays include classical antimalarials
such as methylene blue (Figure 2), a compound in phase
II trials which is consistently found to be active against
transmission, though with ranging IC50 values (e.g. 12–
490 nM). Artemisinin endoperoxides have generally
proven inactive (>1 mM) against mature gametocytes.
One of the first gametocyte-centred screens used the
MMV malaria box, aimed at the identification of dual
asexual-sexually active drug candidates. Gametocytaemia
was determined following expression of a transgenic
gametocyte-specific protein pfs16-Luc-GFP marker, with
cell viability determined using Mitotracker Red, a
reporter of mitochondrial function [46]. Other studies
have used similar strategies as a base for drug screening
[47–49]. In parallel to these efforts, a group from Glax-
oSmithKline developed a methodologically improved
ATP bioluminescent assay, using reduction in ATP as
a marker of cell injury and death [50]. Using this method,
the group tested 17 gold-standard compounds with
known antimalarial activity on purified stage IV–V game-
tocytes, before cytotoxicity and specificity tests with
HepG2 cells. A follow-up screen examined dual activity
of the TCAMS library against stage V gametocytes [51].
Towards an improved signal-to-noise ratio, required for
HTS, several groups have developed colorimetric read-
outs for gametocyte viability. This includes parasite lac-
tate dehydrogenase (pLDH) [52] and alamarBlue [53] as
indicators of metabolic activity. Two recent large-scale
screens are also worth highlighting, including the use of
acridine orange (AO) to measure gametocytaemia and
rounding-up post-activation as a marker of viability,
adapted to 384-well format from researchers at the Isti-
tuto Superiore di Sanita` in Rome [54] and, most recently,
the Saponin-lysis Sexual Stage Assay (SaLSSA) from the
University of California San Diego School of Medicine.
[11]. This latter assay utilises synchronised gametocytes
and involves an in situ erythrocyte saponin-lysis before
MitoTracker Red staining, highlighting parasites with an
active mitochondrial membrane potential. Because it can
work at low magnification, this automated high content
imaging platform has been developed to 1534-well capac-
ity and has been used effectively with several drug
libraries [11] (Figure 1).
Sex specificity and viability
One of the key challenges, however, to drug discovery of the
transmission stages, is the in vivo validation of hits. Most
screens to date, validate any newly discovered hits with the
Standard Membrane Feeding Assay (SMFA) [55] to deter-
mineonwardsviability.Althoughwidelyconsideredthegold-
standard for transmission blocking activity, the assay is
extremely  low-throughput. It involves treatment of gameto-
cyte culture before feeding to malaria-susceptible Anopheline
mosquitos using an artificial membrane. Mosquito midguts
are then dissected 7–10 days after feeding and oocyst abun-
dance is counted by microscopy to determine viability [56].
Attempts to increase throughput have been made and hold
great promise if robustness and reproducibility in mosquito-
feeds can be achieved [57]. What use of the SMFA demon-
strates is that viability of the sexual stages is not the same
thing as capacity to transmit (i.e. gametocytaemia does not
equate with transmission). For example, it is clear that many
exemplar transmission-blocking drugs like primaquine do
not affect the presence of viable (but transmission-incompe-
tent) gametocytes in peripheral blood [58]. Meeting this
challenge head on, a very different approach to transmission
screening is to explore the effect of drugs not on gametocytes
but on the developing gametes, mimicking their transforma-
tion in the mosquito midgut ex vivo without the limitations of
the SMFA. P. falciparum notably has a female-biased sex
ratio, with a range of ratios of between 3 and 5 females for
every 1 male [59,60]. Combined with the fact that males
exhibit an increased susceptibility to known antimalarials
despite the greater abundance of females [59], has prompted
development of assays that capture both male and female
development independently. One of the most successful of
these is the Dual Gamete Formation Assay (DGFA) [12,59],
which measures male and female gametogenesis via auto-
mated imaging. Male gamete formation is signified by for-
mation of ‘exflagellation centres’ as male gametes adhere to
neighbouring erythrocytes; female gamete formation is
detected by immunostaining of a surface protein expressed
at the gamete surface upon egress. In measuring these two
features, the assay provides a sex-specific gametocyte viabil-
ity readout and has been developed to plate-based format
[12]. Similar male-only [61] and female-only assays have also
been developed [62]. Because of each entity’s focus on
gamete formation, stage V gametocyte viability is encom-
passed in each assay since it is the only stage that will develop
further upon triggering gametogenesis. The assay has proven
to be a powerful high-throughput proxy for transmission and
there is good evidence of a linear correlation between sex-
specificgameteassaysandSMFAactivity [12,63].However,a
key caveat that remains with each of these assays is the viable
production of in vitro-derived stage V P. falciparum gameto-
cytes that are competent for exflagellation and onward trans-
mission to mosquitoes [43].
Advancement of the DGFA to 384-well plate format
recently permitted an HTS of the University of Dundee
Global Health Chemical Diversity Library (GHCDL), in
which the DGFA was undertaken in parallel to ABS and
other transmission blocking assays to discern compounds
with varying activity profiles. The joint study between
Imperial College London and GlaxoSmithKline [64] is
6 Next Generation Therapeutics
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the largest transmission blocking focussed screen carried
out to date on a non-biased library (i.e. a library unrelated
to ABS activity). Numerous hits were identified display-
ing asexual-specific, dual asexual-sexual stage, sexual
stage-specific and, for the first time, gamete-specific
targeted activity. Of note, male specific, dual male-female
gametocyte and male gamete only targeted compounds
were also discovered. Among hits, several belonged to a
cluster sharing an N-((4-hydroxychroman-4-yl)methyl)-
sulphonamide scaffold, which shows promise for future
transmission-only drug development (Figure 2).
The GHCDL screen, like many others, demonstrated the
power of combining multiple platforms to find novel scaf-
folds with both new modes of action and multi-stage activity.
A good example of the latter was the discovery of
DDD107498, a translation elongation factor 2 (eEF2)-tar-
geted compound (Figure 2) identified from the Dundee
protein kinase scaffold library, which shows multiple activity
against ABS, liver stages and male and female gamete
formation [65]. Though many groups favour the clinical
development of a multi-stage drug, one caution with this
approach is the challenge that selection for parasite resis-
tance will be amplified by its multiple points of sensitivity
across the lifecycle (presuming it has a single pharmacologi-
cal mode of action across the lifecycle). Combined formula-
tions with drugs targeting different processes in different
stages, in particular transmission, may be preferable in this
case (as it has been with viral and bacterial infections), not
only blocking transmission butprotecting partnerdrugs from
resistance development [64].
Conclusions
Application of HTS technologies to the liver and the
sexual stages of Plasmodium are receiving an increasing
interest as a necessary addition to efforts in antimalarial
drug discovery. Innovation in technologies and novel
modes of action becomes increasingly important in an
era of emerging ACT resistance and the plateau in
declining malaria incidence. Advances in screening for
drugs that act along each step of the parasite lifecycle
(from ABS to transmission and back again) have advanced
significantly in recent years with development of assays
testing activity at each stage. Though these phenotypic
screens exhibit clear advantages over target-based
approaches in their scope, they also raise challenges in
drug mode of action identification. However, by combin-
ing forces with medicinal chemistry to undertake detailed
SAR of hits, the prospect of developing new lifecycle
orientated drugs with new modes of action becomes
increasingly feasible.
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